SCHEMBL16632183

SCHEMBL16632183

CCc1nc2cc(N(C)Cc3ccc(OC)cc3)ncc2cc1-c1ccc(F)c(NC(=O)O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.39
KRAS P01116 2/20 0.39
RAF1 P04049 2/20 0.39
BRAF P15056 2/20 0.39
ALDH1A1 P00352 1/20 0.35
ABL1 P00519 1/20 0.35
FGFR1 P11362 3/20 0.35
KCNH2 Q12809 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
AVPR1B P47901 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15272707 0.92 KDR (0.47) KDRKRASRAF1BRAFABL1
SCHEMBL15289544 0.90 KDR (0.36) KDRKRASRAF1BRAFABL1
SCHEMBL16632292 0.89 ALDH1A1 (0.36) KDRKRASRAF1BRAFALDH1A1
SCHEMBL15289560 0.89 BRAF (0.53) KDRKRASRAF1BRAFABL1
SCHEMBL16632423 0.89 KDR (0.38) KDRKRASRAF1BRAFALDH1A1
SCHEMBL16632663 0.85 ALDH1A1 (0.40) ALDH1A1FGFR1HDAC3HDAC1HDAC2
SCHEMBL16632381 0.83 KDR (0.39) KDRKRASRAF1BRAFALDH1A1
SCHEMBL16632181 0.82 PTGDR (0.46) KDRKRASRAF1BRAFABL1
SCHEMBL15289520 0.82 RAF1 (0.45) KDRKRASRAF1BRAFABL1
SCHEMBL16632505 0.82 KDR (0.46) KDRKRASRAF1BRAFALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187474-B2 Raf inhibitor compounds DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-17 US disclosed
US-20150105367-A1 RAF INHIBITOR COMPOUNDS DECIPHERA PHARMACEUTICALS, LLC 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105367-A1 RAF INHIBITOR COMPOUNDS BRAF, RAF1, NRAS KDR 806/4885KRAS 4/4885RAF1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.